Flotek Industries Inc/Cn/FTK

Flotek Industries Inc (CN) limped into the second half of 2026 with $5.7 million of cash, $113.7 million of liabilities, and a headline net income of $4.7 million for the quarter ended 31 March 2026. Behind the numbers, the company’s Form 4 shows executives trading shares with the enthusiasm of bargain-hunters at a closing-down sale: the CEO bought 100,000 shares and sold 75,000 the same day, a 75% instantaneous dilution of optics. Revenue clocked in at $70.1 million, yet operating cash flow delivered a measly $21,000-enough to buy two decent office coffee machines and still have change for a loyalty card.

Flotek peddles chemistry and data analytics to oil and gas operators, promising ‘state-of-the-art products’ and a ‘common value creation platform’ that supposedly maximises customer returns. The slick product pages show colourful diagrams of molecules and pipelines, while the filings reveal a research budget of $396,000 in a quarter that booked $70.1 million of sales. The company’s compliance hotline is outsourced to a third-party service that doubles as a bilingual call centre-hardly the image of a cutting-edge lab. Flotek’s global presence is said to be ‘strategically reinforced’ by production facilities and a distribution network, yet the most recent 10-Q does not quantify production capacity, unit volumes, or utilisation rates, leaving investors to trust the marketing rather than the mechanics.

Filings for the quarter to 31 March 2026 show: revenue of $70.1 million, net income of $4.7 million, diluted EPS of $0.12, operating income of $7.6 million, total assets of $231.8 million, liabilities of $113.7 million, and equity of $118.2 million. Cash and equivalents stood at $5.7 million, operating cash flow was $21,000, and inventory rose by $4.1 million to $14.3 million. R&D spend was $396,000, and the weighted average diluted share count was 38.3 million shares. No dividends were declared, and no buybacks were filed. The company’s own investor-relations site lists earnings calls but no analyst day or capital-markets update, and the latest 8-K announces a ‘first contract to deliver power services for utilities infrastructure support’ without disclosing contract value, duration, or margin assumptions. The SEC submissions JSON confirms a Form 10-Q filed on 7 May 2026 for the quarter ended 31 March 2026.

If the platform story is a glossy brochure, the balance sheet is a damp matchbox. The company’s website promises ‘innovative chemistry solutions’ and ‘data analytics’, yet the only data that appears in the filings is a $396,000 R&D line and a $21,000 operating cash-flow figure. The latest 8-K touts a utilities contract without attaching a dollar value, leaving investors to guess whether it’s a pilot project or a marquee win. The compliance hotline is run by a third-party outfit, which may reassure governance teams but does little for the ‘cutting-edge’ narrative. Without segment-level margins, utilisation metrics, or contract economics, the operating reality remains a black box wrapped in a press-release bow.

The company’s product pages show molecules and pipes, and the filings show molecules of cash and pipelines of liabilities. The gap between the polished story and the plain numbers is wide enough to drive a shale rig through. The evidence does not quantify customer concentration, contract backlog, utilisation rates, or capital-intensity ratios, so every operating claim beyond the filed numbers remains unproven. For a business that trades on ‘innovative chemistry’, the filings provide very little chemistry and even less innovation.

To deepen the file, Flotek could disclose contract economics for the new utilities win, segment-level margins for its chemistry and data-analytics lines, utilisation rates for its production facilities, and a breakdown of inventory ageing. Absent these, the source requires readers to navigate a press-release sauna rather than a research lab.